Home » Stocks » SLGL

Sol-Gel Technologies Ltd. (SLGL)

Stock Price: $10.21 USD 0.27 (2.69%)
Updated May 13, 2021 1:54 PM EDT - Market open
Market Cap 223.80M
Revenue (ttm) 8.77M
Net Income (ttm) -29.29M
Shares Out 23.00M
EPS (ttm) -1.30
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $10.21
Previous Close $9.94
Change ($) 0.27
Change (%) 2.69%
Day's Open 10.00
Day's Range 10.00 - 10.44
Day's Volume 11,833
52-Week Range 7.00 - 16.69

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SolGel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of 63.27% and -59.15%, respectively, for the quarter ended March 2021.

1 hour ago - Zacks Investment Research

- Sol-Gel is in advanced negotiations with a potential partner regarding the commercialization of EPSOLAY ® and TWYNEO ®

7 hours ago - GlobeNewsWire

SolGel Technologies Ltd. (SLGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

6 days ago - Zacks Investment Research

NEW YORK, April 28, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sol-Gel Technologies Ltd. ("Sol-Gel" or the "Company") (NASDAQ: SLGL) Such investors are advised ...

2 weeks ago - PRNewsWire

Cyclerion Therapeutics, Inc. (NASDAQ: CYCN), Sol-Gel Technologies Ltd. (NASDAQ: SLGL), Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), DermTech, Inc. (NASDAQ: DMTK) and Bionano Genomics, Inc. (NASDAQ: BNGO) ...

Other stocks mentioned: BNGO, DMTK, ALDX, CYCN
2 weeks ago - Benzinga

NESS ZIONA, Israel, April 27, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and ...

2 weeks ago - GlobeNewsWire

SolGel Technologies Ltd. (SLGL) was a big mover last session on higher-than-average trading volume.

3 weeks ago - Zacks Investment Research

SolGel Technologies Ltd. (SLGL) witnessed a jump in share price last session on above-average trading volume.

2 months ago - Zacks Investment Research

SolGel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of 12.20% and -725.03%, respectively, for the quarter ended December 2020.

2 months ago - Zacks Investment Research

• Epsolay ® and Twyneo ® PDUFA goal date s set for April 26 , 2021 and August 1 , 2021 respectively

2 months ago - GlobeNewsWire

NESS ZIONA, Israel, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing brande...

2 months ago - GlobeNewsWire

NESS ZIONA, Israel, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing brande...

4 months ago - GlobeNewsWire

Sol-Gel Technologies (SLGL) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

5 months ago - Zacks Investment Research

Patented technology for slow release of topical formulations. Potentially the first single-active benzoyl peroxide to be approved as a prescription drug.

5 months ago - Seeking Alpha

Shares of Sol-Gel Technologies (NASDAQ:SLGL) moved higher by 0.1% after the company reported Q3 results. Quarterly Results Earnings per share increased 0.00% year over year to ($0.37), which beat the es...

6 months ago - Benzinga

NESS ZIONA, Israel, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and g...

6 months ago - GlobeNewsWire

NESS ZIONA, Israel, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing brande...

6 months ago - GlobeNewsWire

NESS ZIONA, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing bra...

8 months ago - GlobeNewsWire

NESS ZIONA, Israel, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded an...

8 months ago - GlobeNewsWire

NESS ZIONA, Israel, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and...

9 months ago - GlobeNewsWire

NESS ZIONA, Israel, July 29, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing an...

9 months ago - GlobeNewsWire

NESS ZIONA, Israel, July 28, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and...

9 months ago - GlobeNewsWire

Generic Product Collaborations between the Companies Now Cover Ten Products Generic Product Collaborations between the Companies Now Cover Ten Products

10 months ago - GlobeNewsWire

NESS ZIONA, Israel, June 16, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing an...

10 months ago - GlobeNewsWire

NESS ZIONA, Israel, May 14, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and ...

11 months ago - GlobeNewsWire

Investment is for ordinary shares and warrants to purchase ordinary shares at a combined price of $11 per ordinary share and accompanying warrants to purchase 0.80 of an ordinary share

1 year ago - GlobeNewsWire

NESS ZIONA, Israel, Feb. 14, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing an...

1 year ago - GlobeNewsWire

Successful topline results, strengthens Epsolay’s long-term safety and tolerability profile in the treatment of papulopustular rosacea

1 year ago - GlobeNewsWire

Sol-Gel Technologies: A Promising Small-Cap Dermatology Player In 2020

1 year ago - Seeking Alpha

NESS ZIONA, Israel, Feb. 05, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”) a clinical-stage dermatology company focused on identifying, developing and...

1 year ago - GlobeNewsWire

The under-the-radar pharma company might have one of the industry's more promising approaches to dermatology treatments.

1 year ago - The Motley Fool

Sol-Gel Shines In Treating 2 Skin Disorders, NDAs Expected For Both Indications In 2020

1 year ago - Seeking Alpha

NESS ZIONA, Israel, Jan. 02, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) today announced the initiation of a Phase 1 proof of concept clinical study of SGT-210, its novel, topic...

1 year ago - GlobeNewsWire

The small-cap company announced promising results from a clinical trial.

1 year ago - The Motley Fool

Sol Gel Technologies (SLGL) news for Monday concerning an acne drug study with incredibly positive results has SLGL stock taking off. The post Sol Gel Technologies News: SLGL Stock Skyrockets 80% on Acn...

1 year ago - InvestorPlace

Shares of the Israel-based, clinical-stage dermatology company Sol Gel Technologies Ltd (NASDAQ: SLGL) were more than doubling Monday.

1 year ago - Benzinga

Shares of Sol-Gel Technologies Ltd. SLGL, -5.82% gained 154% in premarket trading on Monday after the Israeli drugmaker said its acne drug Twyneo met the primary endpoints in two late-stage trials.

1 year ago - Market Watch

NESS ZIONA, Israel, Dec. 30, 2019 (GLOBE NEWSWIRE) --  Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) today announced top-line results from two pivotal Phase 3 clinical trials for Twyneo®, an investigation...

1 year ago - GlobeNewsWire

NESS ZIONA, Israel, Oct. 16, 2019 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) today announced it will present research on the use of its proprietary microencapsulation technology in ...

1 year ago - GlobeNewsWire

Sol-Gel Technologies Ltd. (SLGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

1 year ago - Zacks Investment Research

Sol-Gel Technologies Ltd. said Monday that two late-stage trials of a treatment for papulopustular rosacea produced positive results.

1 year ago - Market Watch

Sol-Gel Technologies Ltd. (SLGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

1 year ago - Zacks Investment Research

About SLGL

Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, w... [Read more...]

Industry
Biotechnology
IPO Date
Jan 23, 2018
CEO
Alon Seri-Levy
Employees
65
Stock Exchange
NASDAQ
Ticker Symbol
SLGL
Full Company Profile

Financial Performance

In 2020, SLGL's revenue was $8.77 million, a decrease of -61.71% compared to the previous year's $22.90 million. Losses were -$29.29 million, 19.0% more than in 2019.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for SLGL stock is "Buy." The 12-month stock price forecast is 20.00, which is an increase of 95.94% from the latest price.

Price Target
$20.00
(95.94% upside)
Analyst Consensus: Buy